Stay updated on SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.

Latest updates to the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check20 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check63 days agoChange DetectedThe web page has undergone significant updates, including the removal of detailed descriptions of a Phase 1 clinical trial for axatilimab and durvalumab, while retaining critical information about dosing and safety protocols. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference40%
Stay in the know with updates to SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.